long intergenic non-protein coding RNA 1802Genealiases: []
Q-omics provides the consensus-scored LINC01802 profile across patient tissues and cancer cell-line models. LINC01802 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01802 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LINC01802 RNA expression shows 6,695 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where LINC01802 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01802 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01802 survival associations across molecular data types. LINC01802 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01802 RNA expression–survival associations across cancer types. High LINC01802 expression shows unfavorable associations in HNSC, MESO, TGCT, UCEC and BRCA, but favorable associations in OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01802 RNA expression.
This table summarizes LINC01802 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01802. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01802 shows lower tumor expression in KIRC, KIRP and PRAD and higher tumor expression in HNSC, KICH and LUSC. The KIRC box plot shows higher LINC01802 RNA expression in normal versus tumor tissue (log2 FC = −2.098, t-test p < 0.001).
This table shows molecular features associated with LINC01802 in patient tissues and cancer cell lines. In patient samples, LINC01802 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
